← Back to Search

Radiation Therapy

Stereotactic Body Radiotherapy for Prostate Cancer

N/A
Recruiting
Led By Robert Meier, MD
Research Sponsored by Swedish Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical stage T1a-T3, N0-Nx, M0-Mx
Patients belonging in one of the following risk groups: (1) LOW RISK: CS T1a-T2a, Gleason 2-6, PSA<10, Nx-0, Mx-0; (2) INTERMEDIATE RISK: CS T2b, Gleason ≤7, PSA<20, Nx-0, Mx-0, or CS T1a-T2b, Gleason 2-6, PSA≥10 & <20, Nx-0, Mx-0, or CS T1a-T2b, Gleason 7, PSA≤20, Nx-0, Mx-0; or (3) HIGH RISK: CS T2c-T3, any Gleason, any PSA, or CS T1-3, Gleason ≥8 and/or PSA≥20
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 years
Awards & highlights

Study Summary

This trial is studying the effects of radiation on prostate cancer patients.

Who is the study for?
Men with prostate cancer can join this trial if they have a confirmed diagnosis, are in good physical condition (Karnofsky score of 70-100), and fall into one of three risk groups based on tumor size, Gleason score, and PSA levels. Hormone therapy is allowed under specific conditions for each risk group.Check my eligibility
What is being tested?
The trial is testing the effects of CyberKnife Stereotactic Radiosurgery—a type of highly focused radiation—on prostate tumors. It aims to see if this method has fewer side effects than standard treatments and how it impacts patients' quality of life over time.See study design
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects from stereotactic radiosurgery may include urinary issues, bowel problems, fatigue, skin reactions at the treatment site, erectile dysfunction, and other radiation-related complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is in an early to mid-stage and may or may not have spread to nearby lymph nodes.
Select...
My prostate cancer is classified as low, intermediate, or high risk.
Select...
I am mostly able to care for myself and carry out normal activities.
Select...
My prostate cancer was confirmed through a tissue examination.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quality of life outcomes (low- and intermediate-risk prostate cancer groups)
Rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicities (high-risk group)
Secondary outcome measures
Disease free survival
Overall survival
Rates of toxicities related to treatment
Other outcome measures
Quality of life

Trial Design

1Treatment groups
Experimental Treatment
Group I: CyberKnife Stereotactic RadiosurgeryExperimental Treatment1 Intervention
This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CyberKnife Stereotactic Radiosurgery
2007
N/A
~380

Find a Location

Who is running the clinical trial?

Swedish Medical CenterLead Sponsor
53 Previous Clinical Trials
8,148 Total Patients Enrolled
2 Trials studying Prostate Cancer
300 Patients Enrolled for Prostate Cancer
Robert Meier, MDPrincipal InvestigatorSwedish Medical Center Radiosurgery Center
1 Previous Clinical Trials
379 Total Patients Enrolled
1 Trials studying Prostate Cancer
379 Patients Enrolled for Prostate Cancer

Media Library

CyberKnife Stereotactic Radiosurgery (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02334579 — N/A
Prostate Cancer Research Study Groups: CyberKnife Stereotactic Radiosurgery
Prostate Cancer Clinical Trial 2023: CyberKnife Stereotactic Radiosurgery Highlights & Side Effects. Trial Name: NCT02334579 — N/A
CyberKnife Stereotactic Radiosurgery (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02334579 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of individuals participating in this clinical experiment?

"Affirmative. Evidentiary information located on clinicaltrials.gov confirms that this clinical trial, first posted on December 1st 2014, is actively recruiting subjects. 146 people need to be enrolled across a single site."

Answered by AI

Are there openings for participants in this experiment?

"According to clinicaltrials.gov, this investigation is currently assembling a cohort of participants; its initial posting was on December 1st 2014 and it has been updated as recently as July 11th 2019."

Answered by AI

Who else is applying?

What state do they live in?
New York
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
2014. "Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02334579.
All > Prostate Cancer > Washington
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top